Biotech Values

[pollyvonwog]

I agree that it will take quarter numbers to actually start to move MNTA as people are certainly skeptical and you're right that overhang is there and will remain there. In regards to your 8 quarter case, you're neglecting that generic Copaxone will more than likely be on the market by then, to which there are no potential generic competitors.

If the FDA wants full characerization, than TEVA will not get approved. If FDA lowers the bar, which in my opinion they will not, then yes TEVA very well could get it. So back to my original question, why do you think TEVA will get approval? This isn't a rhetorical question, I really want to know your thoughts on why.